M&T Bank
AEGR

M&T Bank’s Aegerion Pharmaceuticals AEGR Stock Holding History

M&T Bank’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,500
Closed -$106K – 1261
2013
Q4 		$106K Buy
+1,500
New +$115K ﹤0.01% 569

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

M&T Bank's AEGR Position: Q1 2014 in Review

M&T Bank sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2014, closing a stake of 1,500 shares — an estimated $106K sold.

M&T Bank first reported a position in AEGR in Q4 2013 and held it in 1 quarter. The position peaked at $106K in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q1 2014.

  • M&T Bank reported no remaining Aegerion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • M&T Bank sold 1,500 Aegerion Pharmaceuticals shares in Q1 2014, an estimated $106K.
  • M&T Bank first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • M&T Bank's Aegerion Pharmaceuticals position peaked at $106K in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2014.

Based on M&T Bank's 13F filing for Q1 2014, filed 14 May 2014.